Beyond excited to present the results of our investigator-initiated #CLONEVO trial at #ASCO25 ASCO! 🏢Arie Crown Theater on May 31, 2025 🕐 Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in: ✅ 31% pathologic downstaging ✅ Clear

Live at #ASCO25: Dr. Bishoy Faltas (Dr. Bishoy M. Faltas) presented results from the CLONEVO #ClinicalTrial for #BladderCancer that he led with other Weill Cornell Medicine #GU team members bit.ly/3Z67KoD

Watch Dr. Bishoy Faltas (Dr. Bishoy M. Faltas) discuss #research he presented at #ASCO25 evaluating abemaciclib for certain patients with muscle-invasive #BladderCancer and how this study offers hope for this patient population bit.ly/3Z67KoD

Grateful for the opportunity to present our CLONEVO investigator-initiated trial (IIT) in bladder cancer at ASCO #ASCO2025. Here are some lessons I learned along the way: Investigator-initiated trials (IITs) are essential. IITs are clinical trials independently designed and led

Congrats!!! Ilana and Kent. Great work

🚨Roadmap 🚨 Alice Soragni Soragni:Lab, Erik S. Knudsen Roswell Park & Co discuss the mechanisms of acquired resistance and the models to better study it to advance predictive and proactive prevention in cancer therapy. 📖 ⬇️ bit.ly/3Hv6qpj

In nature: SFXN1 promotes bladder cancer metastasis by restraining PINK1-dependent mitophagy. Click here to read the article: nature.com/articles/s4138…

#CGCecDNA starts tomorrow! We can’t wait to hear from our stellar line up of speakers at the first instalment of the Cancer Grand Challenges Conference Series focused on extrachromosomal DNA. See you at the The Royal Society. Click here for more info: bit.ly/4jEpmiI

Research at risk: Weill Cornell Medicine’s Nancy Du received a $500K grant from the Congressionally Directed Medical Research Programs at Department of Defense 🇺🇸 to research metastatic #Cancer, but a stop-work order in April brought her work to a halt. news.cornell.edu/stories/2025/0…

🔎 Dr. Bishoy M. Faltas gives an overview of the #CLONEVO study, which is the first window-of-opportunity trial of a CDK4/6 inhibitor—abemaciclib—in muscle-invasive #bladdercancer: buff.ly/xNdrNug

Honored to be nominated to the Executive Committee of the Society for Basic Urologic Research Society for Basic Urologic Research | SBUR! If elected, I’ll work to expand the society’s scientific scope, enhance mentorship pathways, and foster collaborations that empower the next generation of investigators.

Deeply grateful to BCAN for this incredible honor receiving the YIA! Truly fortunate to be trained by the best Dr. Bishoy M. Faltas ! Grateful for support from Weill Department of Medicine WCM GU Cancer & collaboration with WCM Englander Institute for Precision Medicine NY Genome Center Excited to be part of advancing bladder cancer research

We’re Blainey Lab sharing a major update to CROPseq-multi, our versatile system for CRISPR screens that is compatible with individual and combinatorial perturbations, diverse SpCas9-based technologies, and multiple high-content, single-cell readouts. biorxiv.org/content/10.110…

Today we at WCM Englander Institute for Precision Medicine submitted our response to the NIH's call for a national AI strategy, titled "Leading the Transformation: A National Artificial Intelligence Strategy for the NIH" Dr. Bishoy M. Faltas Cora Sternberg Jan Krumsiek Iman Hajirasouliha 1/6

Great opportunity!!! Dr. Bishoy M. Faltas

😍🥰congrats!!!. Hsieh Lab. Well deserved.

Don't miss the latest UroToday.com Expert Commentary "Circulating Tumor #DNA Assay in Non-Muscle-Invasive #BladderCancer," by our Chief Research Officer Dr. Bishoy Faltas (Dr. Bishoy M. Faltas)! urotoday.com/recent-abstrac…

Writing is thinking | Nature Reviews Bioengineering nature.com/articles/s4422…

Lewis Au highlighting the importance of tumor heterogeneity in biomarker finding for adjuvant therapy in RCC ANZUP #ANZUP25

Always a pleasure discussing with Jonathan Rosenberg MD Ashish M. Kamat, MD, MBBS UroToday.com on bladder Ca! Fred Hutch Cancer Center